Cns Pharmaceuticals Stock Beneish M Score

CNSP Stock  USD 0.13  0.01  8.33%   
This module uses fundamental data of Cns Pharmaceuticals to approximate the value of its Beneish M Score. Cns Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Cns Pharmaceuticals Piotroski F Score and Cns Pharmaceuticals Altman Z Score analysis.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.
  
At this time, Cns Pharmaceuticals' Short and Long Term Debt Total is relatively stable compared to the past year. As of 11/22/2024, Short and Long Term Debt is likely to grow to about 362.4 K, while Debt To Equity is likely to drop (0.07). At this time, Cns Pharmaceuticals' Days Of Payables Outstanding is relatively stable compared to the past year.
At this time, Cns Pharmaceuticals' M Score is unavailable. The earnings manipulation may begin if Cns Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Cns Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Cns Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-17.75
Beneish M Score - Unavailable
Elasticity of Receivables

N/A

Focus
Asset Quality

0.98

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

1.01

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

1.11

Focus

Cns Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Cns Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Assets1.6 M1.7 M
Notably Down
Slightly volatile
Total Current Assets1.5 M1.6 M
Notably Down
Slightly volatile
Property Plant Equipment15.4 K14.5 K
Notably Up
Slightly volatile
Selling General Administrative3.6 M4.8 M
Way Down
Slightly volatile
Total Current Liabilities6.4 M6.1 M
Sufficiently Up
Slightly volatile
Short Term Debt362.4 K300.8 K
Fairly Up
Slightly volatile

Cns Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Cns Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Cns Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Cns Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Cns Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

4,340.7

At this time, Cns Pharmaceuticals' Depreciation And Amortization is relatively stable compared to the past year.

Cns Pharmaceuticals Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Cns Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Total Assets7.9M15.9M8.8M13.1M1.7M1.6M
Total Current Assets7.9M15.5M7.5M12.6M1.6M1.5M
Non Current Assets Total18.2K357.6K1.3M488.5K109.7K104.2K
Depreciation And Amortization2.0K11.1K13.1K11.8K4.1K4.3K
Selling General Administrative2.0M4.4M4.7M6.0M4.8M3.6M
Total Current Liabilities311.0K1.9M2.1M4.9M6.1M6.4M
Non Current Liabilities Total445.8K289.5K1.4M1.9M4.1M0.0
Net Debt(7.2M)(13.6M)(4.6M)(9.6M)(247.9K)(260.3K)
Operating Income(3.8M)(9.5M)(14.0M)(15.3M)(18.9M)(17.9M)
Total Cash From Operating Activities(3.6M)(7.3M)(13.5M)(10.6M)(14.1M)(13.4M)

About Cns Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cns Stock

  0.76VALN Valneva SE ADR Downward RallyPairCorr
  0.72VCNX VaccinexPairCorr

Moving against Cns Stock

  0.73BMY Bristol Myers SquibbPairCorr
  0.71GILD Gilead SciencesPairCorr
  0.69EWTX Edgewise TherapeuticsPairCorr
  0.62VRDN Viridian TherapeuticsPairCorr
  0.6KZR Kezar Life SciencesPairCorr
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.